The tweet was deleted by the author.
But we saved everything 🙂.
Esperion Therapeutics unveiled data from its CLEAR Outcomes trial and the CLEAR PATH Phase 2 pediatric study at the European Atherosclerosis Society Congress 2026.
The presentations focused on advances in lipid-lowering therapies and their impact on pediatric and adult populations at risk for atherosclerotic cardiovascular disease. The new findings may inform future treatment guidelines and ongoing clinical development for cholesterol management in younger patients.
Earlier this year, Esperion Therapeutics estimated that U.S. heart failure care costs total $46 billion annually, according to company projections in a recent analysis. The company advocated for optimized therapy and increased patient education in the same statement. These initiatives coincide with Esperion’s continued focus on addressing cardiovascular risks across different age groups.